Semaglutide vs Tirzepatide for Weight Loss — Which GLP-1 is Better?

Medically reviewed by Dr. Dan Xu, M.D., CCFP — CPSO Licensed Physician and Founder & Medical Director of ID Cosmetic Clinic, Markham. Last updated June 2026.

“Should I take Ozempic or Mounjaro?” is one of the most common questions patients bring to our Markham clinic — usually after seeing dramatic before-and-after results online. The honest answer is that there is no single winner. Semaglutide and tirzepatide are both GLP-1 weight-loss medications, they share overlapping mechanisms, but they were designed differently and perform differently in trials. This guide breaks down exactly how each one works, who tends to do better on which, what the side effects feel like, how much they cost in Canada, and — importantly for an aesthetic clinic — how to manage the facial volume loss (“Ozempic face”) that rapid weight loss can cause. Our goal is to send you into a prescriber’s consultation already knowing the right questions to ask.

Please note: This is general medical-education information, not medical advice or a prescription. Both semaglutide and tirzepatide are prescription-only medications that must be assessed and prescribed by a licensed physician. ID Cosmetic Clinic’s expertise in this topic is the facial-aesthetic side of weight loss — restoring and protecting facial volume as you slim down. Do not start, stop, switch, or dose these medications based on this article or on someone else’s regimen.

Semaglutide vs tirzepatide — at a glance

Weight-loss percentages are averages from pivotal trials at the highest approved doses; individual results vary widely. Pricing depends on dose, brand, pharmacy and insurance coverage — confirm with your prescriber and pharmacist. (Figures to be confirmed before publishing.)

Which one is right for you?

The decision is a clinical one made with a prescribing physician, but here is the framework most doctors weigh:

• Choose semaglutide if your target is a moderate, sustainable loss (roughly 10–15% of body weight), you want the option with the most mature safety data and the widest global use, you have a cardiovascular history that may benefit from its proven heart-outcome data, or you are starting a GLP-1 for the first time and prefer the most well-trodden path.
• Choose tirzepatide if you have a higher weight-loss target (20%+), a higher BMI that calls for a stronger tool, significant insulin resistance or metabolic syndrome that may benefit from the dual mechanism, or you plateaued on semaglutide and want to step up — and you are comfortable with a medication whose very-long-term data is still being collected.
• Let your physician decide based on your medical history (thyroid, pancreatitis, kidney function), current medications, insurance and provincial coverage, and any previous GLP-1 experience. These factors often matter more than the headline weight-loss numbers.
• Plan facial maintenance either way (see below). Both medications can cause “Ozempic face” — and because tirzepatide tends to drive more weight loss, that facial change can appear sooner or more noticeably in some patients. This is where an aesthetic clinic fits into your weight-loss journey.

Semaglutide: the proven GLP-1 pioneer

Semaglutide is a GLP-1 receptor agonist — it mimics GLP-1, a hormone your gut releases after eating. It works on three fronts: it prompts glucose-dependent insulin release from the pancreas, it acts on the brain’s appetite centres to increase fullness and reduce hunger, and it slows stomach emptying so food stays in your system longer. For weight loss, the appetite and gastric-emptying effects matter most — most people notice a clear drop in hunger and in cravings for high-calorie food within the first week.

• How it works: single-target GLP-1 activation reduces appetite, increases satiety, and slows digestion, so you naturally eat less.
• Best for: moderate, sustainable weight loss; first-time GLP-1 users; patients with cardiovascular disease who may benefit from its outcome data.
• The evidence: in the STEP 1 trial, adults with overweight or obesity (without diabetes) on Wegovy 2.4 mg lost about 15% of body weight over 68 weeks, versus about 2.4% on placebo — a landmark result when it published. The SELECT trial later showed a meaningful cardiovascular benefit in patients with obesity and established heart disease.
• Strengths: the most mature safety and outcomes data; the broadest prescriber experience with dose escalation and side-effect management; reliable availability in Canada (Ozempic and Wegovy are both approved).
• Limitations: average weight loss is somewhat lower than tirzepatide; some patients plateau once they reach the maximum dose.

Tirzepatide: the dual-target newcomer

Tirzepatide is more sophisticated: it activates two receptors at once — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP receptors are found in fat tissue and the brain, and the working theory is that GIP and GLP-1 act synergistically — GIP signalling appears to make fat tissue more responsive to GLP-1, producing a “1 + 1 > 2” effect on appetite and fat handling. Tirzepatide also tends to improve insulin sensitivity more than single-target agents, which can matter for patients with metabolic syndrome.

• How it works: dual GLP-1/GIP activation suppresses appetite and improves metabolism more strongly than single-target therapy in head-to-head data.
• Best for: higher weight-loss targets; higher BMI; significant insulin resistance; patients who stalled on semaglutide and want to escalate.
• The evidence: in SURMOUNT-1, adults with overweight or obesity (without diabetes) on the 15 mg dose lost about 20.9% of body weight over 72 weeks, with a large share of the highest-dose group losing more than 20% — numbers that exceed the established single-target data.
• Strengths: the strongest weight-loss results among currently approved medications; broader metabolic improvement (lipids, insulin resistance); a useful option when single-target therapy underperforms.
• Limitations: shorter track record, so multi-year safety data is still accumulating; availability differs in Canada (Mounjaro is approved for type 2 diabetes, while the obesity-specific Zepbound pathway differs from the U.S.); prescribers have comparatively less long-run experience with it.

Side effects: which is easier to tolerate?

Because they share the GLP-1 mechanism, the two medications have very similar side-effect profiles. The gastrointestinal tract is where most effects show up:

• Nausea — the most common; usually worst in the first days after a dose increase, then eases as your body adapts.
• Vomiting — less common than nausea, often linked to eating too much or too quickly.
• Constipation — both slow gastric emptying, so hydration and dietary fibre matter.
• Diarrhea — some patients early on; usually short-lived.
• Acid reflux — a minority report worsened reflux.

In comparative studies, tirzepatide’s GI side-effect rates (especially nausea and vomiting) are broadly similar to semaglutide’s, and some data suggest slightly better GI tolerability for tirzepatide — but individual variation is large, and you cannot predict in advance which medication will sit better with you. Slow, careful dose escalation is the single most effective way to minimise side effects with either drug.

Serious but rare risks: both product labels warn against use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Acute pancreatitis and gallbladder disease are recognised risks. These are physician-level decisions made after a full assessment. This is general information, not medical advice.

“Ozempic face”: the aesthetic side of rapid weight loss

Whether you take semaglutide or tirzepatide, fast and significant weight loss has one shared cosmetic consequence: facial fat shrinks along with body fat, producing what is widely called “Ozempic face” — hollowing below the cheekbones, deepening tear troughs, and softening of the facial contour, which can make the face look more tired and older than the person’s actual age.

The larger the weight loss, the more pronounced this tends to be. Because tirzepatide often drives more total loss, some patients on it notice facial volume change earlier or more clearly than they would on semaglutide. The face is also one of the first places people see the change, even when the rest of the body result is exactly what they wanted.

This is precisely where an aesthetic clinic fits into a weight-loss journey. At ID Cosmetic Clinic in Markham, we work with patients who are losing weight on GLP-1 medications to restore and — ideally — protect facial volume as they go, so the body result is not undercut by a gaunt face. Common, physician-led approaches include:

• Collagen-stimulating injectables (e.g. Sculptra-type poly-L-lactic acid): rebuild your own collagen to restore deep facial support gradually and naturally — well suited to “active maintenance” during ongoing weight loss.
• Hyaluronic-acid dermal fillers: immediate, precise replacement of volume in specific hollows such as tear troughs and the cheeks, for targeted contour correction.
• Calcium-hydroxylapatite fillers (e.g. Radiesse-type): combine immediate volume with collagen stimulation.
• Skin-tightening energy treatments (e.g. Ultherapy or radiofrequency): address the skin laxity that can accompany substantial weight loss.

Our consistent advice: if you are starting a GLP-1, plan facial maintenance at the same time, not after the volume is already gone. Early, conservative intervention usually looks more natural and needs less product than a late rescue. Because our practice primarily serves Asian faces, we tailor placement and product choice to the way these faces age and the way facial fat redistributes during weight loss.

Can you combine or switch between them?

You do not take semaglutide and tirzepatide together — they target overlapping pathways, and combining them is not a recognised protocol. The relevant question is usually switching. Yes, switching is possible, but only under a physician’s supervision and with a fresh dose-escalation plan: moving from semaglutide to tirzepatide generally means restarting at a low dose and titrating up, not swapping milligram-for-milligram. Common reasons to switch include poor tolerance of one drug, a weight-loss plateau, or wanting to step up to a stronger option. The aesthetic plan, by contrast, does combine cleanly with either medication — facial-volume maintenance runs alongside whichever GLP-1 you and your prescriber choose.

Who is not a good candidate?

These are effective, widely used medications, but they are not for everyone. You may not be a candidate, or may need to wait or choose differently, if you:

• are pregnant, breastfeeding, or planning pregnancy in the near term;
• have a personal or family history of medullary thyroid carcinoma, or MEN2;
• have a history of pancreatitis or significant gallbladder disease;
• have severe gastrointestinal disease or gastroparesis (delayed stomach emptying);
• have certain kidney-function concerns or are prone to dehydration from GI side effects;
• have an eating disorder or a history of one, where appetite-suppressing medication may be unsafe;
• are taking medications that require careful timing because of slowed gastric emptying.

For the facial-aesthetic treatments described above, separate contraindications apply — active skin infection in the treatment area, pregnancy or breastfeeding, certain autoimmune or healing conditions, or a history of reaction to a given filler. A qualified physician should confirm suitability for both the medication and any aesthetic treatment in person. This is general information, not medical advice.

What results should you realistically expect?

Neither medication is a “set it and forget it” cure. GLP-1 therapy works best as a tool alongside lifestyle change — not a replacement for it. To get the most out of either drug and to protect your result, you still need to adjust how you eat (fewer ultra-processed foods, adequate protein) and stay active, with resistance training being especially valuable for preserving muscle as you lose weight. Weight tends to be maintained while you stay on therapy and keep up the lifestyle work; regain is common after stopping, which is why the decision to start should be made with a long-term plan in mind. And because the face changes as the body does, the most satisfied patients are usually those who planned facial maintenance from the start rather than scrambling to fix “Ozempic face” later.

How much does GLP-1 weight loss cost in Canada?

Medication cost depends on the brand, your dose, your pharmacy, and whether you have insurance or provincial coverage. Facial-maintenance cost depends on how much volume needs restoring and which approach is used. As a general guide:

(Exact ID Cosmetic Clinic facial-treatment pricing to be inserted before publishing; medication pricing comes from your prescriber and pharmacy.) Be cautious of GLP-1 sold far below market or without a real medical assessment — prescription weight-loss medication should always involve a licensed physician.

Why see ID Cosmetic Clinic for the facial side of weight loss?

Facial volume work during weight loss is judgement-intensive — too little and the face still looks gaunt, too much and it looks unnatural. At ID Cosmetic Clinic in Markham, every facial plan is led by Dr. Dan Xu, M.D., CCFP — a CPSO Licensed Physician, official Allergan/Juvéderm trainer in North America, Top 1% Bellafill injector, Clinical Preceptor at McMaster University Medical Program, and Founder & Medical Director of the clinic since 2017, with 8+ years and 5,000 clients · 80,000 treatment areas of experience. Our practice primarily serves Asian faces, so we plan volume restoration around how these faces age and how facial fat redistributes during rapid weight loss — restoring a natural, rested look rather than simply “filling.”

Frequently asked questions

Is semaglutide or tirzepatide better for weight loss?

In clinical trials, tirzepatide produced more weight loss on average (around 20–22% of body weight) than semaglutide (around 15%). But “better” depends on your goals, health history, side-effect tolerance and what is available to you. Semaglutide has the more mature safety data and proven cardiovascular benefit; tirzepatide has the stronger weight-loss numbers. A prescriber should help you choose.

Is tirzepatide legally available in Canada?

Semaglutide (Ozempic and Wegovy) is authorized in Canada. Tirzepatide (Mounjaro) is authorized in Canada for type 2 diabetes; the obesity-specific Zepbound pathway differs from the U.S. Speak with a licensed prescriber about current availability and legitimate access — avoid unverified online sources.

Can I switch from Ozempic to Mounjaro?

Switching is possible but must be done under a physician’s supervision with a fresh dose-escalation plan. You generally restart at a low dose and titrate up rather than swapping the same milligrams. Common reasons are poor tolerance, a weight-loss plateau, or wanting a stronger option — but you should not switch on your own.

I’m already on Ozempic — will Mounjaro work better for me?

If you have plateaued or want to lose more, there is a clinical rationale for switching to tirzepatide’s dual mechanism. However, some patients do not respond to a new drug as hoped. Your physician should weigh your current progress, metabolic markers, side effects and overall health before any change.

Do these drugs have more side effects if they cause more weight loss?

Not necessarily in proportion. Tirzepatide causes more weight loss, yet its gastrointestinal side-effect rates are broadly similar to semaglutide’s, and some studies suggest slightly better tolerability. Individual variation is large, so you cannot predict which medication will sit better with you until you try it under supervision.

What is “Ozempic face” and can it be treated?

“Ozempic face” is the facial hollowing and skin laxity that can follow rapid weight loss, as facial fat shrinks along with body fat. It can be treated and largely prevented with collagen-stimulating injectables, hyaluronic-acid fillers, and skin-tightening treatments. Starting facial maintenance early in your weight-loss journey usually looks more natural and needs less product than waiting.

Does tirzepatide cause worse “Ozempic face” than semaglutide?

Not by a different mechanism — both cause facial volume loss the same way, through fat reduction. But because tirzepatide often produces more total weight loss, the facial change can appear earlier or more noticeably in some patients. The aesthetic plan is the same: restore and protect facial volume as you lose weight.

Do I still need to diet and exercise on a GLP-1?

Yes. GLP-1 medications work best as a tool alongside lifestyle change, not a replacement for it. Adequate protein, fewer ultra-processed foods, and resistance training (to preserve muscle) all improve your result and reduce regain after stopping.

Will I regain the weight if I stop the medication?

Regain is common after stopping, which is why the decision to start should include a long-term plan. Maintaining lifestyle changes helps, but many people regain a meaningful portion of lost weight once off therapy. Discuss the long-term plan with your prescriber before starting.

Does ID Cosmetic Clinic prescribe these weight-loss medications?

This article is medical-education content; GLP-1 medications are prescription-only and require a physician assessment. ID Cosmetic Clinic’s expertise here is the facial-aesthetic side of weight loss — restoring and protecting facial volume so your body result is not undercut by a gaunt or tired-looking face. Book a consultation to plan facial maintenance alongside your weight-loss program.

Related at ID Cosmetic Clinic

• Treatment: Sculptra collagen stimulation · Dermal fillers · Ultherapy skin tightening
• Concern: Facial volume loss & hollowing
• Read next: How to prevent and treat “Ozempic face” · Sculptra vs dermal filler